CNBX Pharmaceuticals Inc.
cnbxpharmaceuticals.comAI Executive Summary
AI-powered analysis of 10-Q filing content
CNBX Pharmaceuticals shows severe financial distress with negative stockholders' equity exceeding -$2.5 million, minimal cash reserves of only $12,154, and total liabilities of $2.5 million including substantial related party debt. The company has added a new $75,000 short-term loan while cash declined 20% from August 2025 to February 2026, indicating critical liquidity constraints for this cannabis pharmaceutical startup.
Red Flags Detected (7)
Stockholders' equity deficit of approximately -$2.53 million
Cash position critically low at $12,154 (down from $15,111)
Total liabilities of $2.55 million against only $14,899 in assets
4 more red flags detected
Key Takeaways
Company is technically insolvent with liabilities exceeding assets by massive margin
Operating as cannabis pharmaceutical exposes company to complex regulatory environment
2 more takeaways
Filing Overview
What This Means
Deteriorating Trend: Conditions are worsening compared to previous filings. This may create opportunities for service providers.
Quarterly Report: Interim filing with unaudited financial data for the quarter.